<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190602043787N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-07-07</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>Effect of vitamin B1on septic shock patiens</public_title>
      <acronym></acronym>
      <scientific_title>Effectiveness of initial administration of thiamine in patients with septic shock in  patients admitted in  the adult  intensive care unit</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-02-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>70</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/42735</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: randomization with quadruple blocks with individual units is used.it is randomization tool with opaque and sealed envelopes.permuted block randomization with quadruple blocks are used to create randomization.according to the sample size which is 70 people,20 blocks will be produced using the site www.sealedenvelope.com.hidden allocation is using opaque and sealed envelopes, Blinding description: Participants,researchers,healthcare providers (Physicians, nurses, etc.) , data collectors, data analyzer and those who evaluate the outcome , are blinded  to the treatment prescribed. For the control group, placebo was prescribed which was similar in  shape and color and size of the drug.</study_design>
      <phase>3</phase>
      <hc_freetext>Septic shock.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: These patients are given two 100 miligram Vitamin B1 pills that each contains 100 miligram Vitamin B1 and manufactured by Daroopakhsh/Iran, twice daily for 7 days per oral. Intervention 2: Control group: in the control group we will give placebo tablet  twice daily for 7 days per oral .the placebo will be similar in color,taste,shape and administration to the intervention group, not just the therapeutic effect.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Zahra Ataee</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Avesina Ave,Emam Reza hospital</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9137913316</zip>
        <telephone>009838543031</telephone>
        <email>ataeez@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Zahra Ataee</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Avesina Ave, Emam Reza hospital</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9137913316</zip>
        <telephone>+98 51 3854 3031</telephone>
        <email>ataeez@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Ages over 18 years old
Patients with septic shock(a patient that meets the criteria for sepsis and despite adequite fluid thrapy needs vasopressor to preserve MAP ≥  65mmhg and serum lactate is greater than 2 mmol)
Complete informed consent form in the first stage of legal guardianship and in case of failure we refer to the judge of the country
Serum lactate is greater than 2 mmol/li
Hypotention(systolic BP less than 90 mmhg  despite adequite fluid thrapy needs vasopressor(Dopamin ≥ 5mcg/kg/min or Phenylephrine)
Refusal to participate in any other intervention research project</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Liver failure or dysfunction(AST OR ALT &gt;240 unit/li or known cirrhosis) based on previous findings that patients with liver dysfunction may have increased levels of thiamine.
Indication of receiving thiamine(Alcohol abuse)
Other causes of increased lactate levels(seizure in 3 hours)
Prescription of high-levev lactate -like drugs (Linezolid-Methformine)by your phicision
Cyanide or CO poisoning
Known mitochondrial disease
Known or suspected ischemia of the intestine or other organs</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>R65.21</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Severe sepsis with septic shock</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: These patients are given two 100 miligram Vitamin B1 pills that each contains 100 miligram Vitamin B1 and manufactured by Daroopakhsh/Iran, twice daily for 7 days per oral.</i_keyword>
      <i_keyword>Control group: in the control group we will give placebo tablet  twice daily for 7 days per oral .the placebo will be similar in color,taste,shape and administration to the intervention group, not just the therapeutic effect.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Mortality within  hospitalization. Timepoint: 28-day hospital mortality rate. Method of measurement: Patient mortality rate.</prim_outcome>
      <prim_outcome>Duration of hospitalization in  Intensive Care Unit. Timepoint: From the begining to the end of admition in  Intensive Care Unit. Method of measurement: Number of days.</prim_outcome>
      <prim_outcome>Level of serum lactate. Timepoint: At 0 and 24 hours after intervention. Method of measurement: By examining blood plasma by the method of euthoanalyzer.</prim_outcome>
      <prim_outcome>Illness severity. Timepoint: Information on the  Acute physiology and cronic health evaluation (APACHE II) questionnaire is collected once a week and Sequential organ  failure assessment ( SOFA) questionnaire is collected every other day. Method of measurement: By index Sequential organ  failure assessment ( SOFA) and  Acute physiology and cronic health evaluation (APACHE II )  questionnaire.</prim_outcome>
      <prim_outcome>Level of serum thiamine. Timepoint: At 0  hours after intervention. Method of measurement: High-performance liquid Chromatography(HOLC) with normal reference range 16-48 ng/ml.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-02-01</approval_date>
        <contact_name>Ethics committee of Mashhad  University of Medical Sciences</contact_name>
        <contact_address>Quraish bilding of MUMS, daneshghah St, Mashhad, Iran Mashhad Mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
